Astellas Homepage | Astellas Innovation Management LLC

News

News / General News

Jul 17, 2019

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

News / General News

Jul 17, 2019

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

News / General News

Jul 10, 2019

Launch of Smyraf^® Tablets - Provides a new therapeutic option for rheumatoid arthritis in patients who have an inadequate response to conventional therapies -

News / General News

Jun 18, 2019

HYPERCHOLESTEROLEMIA DRUG REPATHA^® SC INJECTION RECEIVES SUPPLEMENTAL INDICATION APPROVAL AS MONOTHERAPY FOR TREATING HYPERCHOLESTEROLEMIA PATIENTS NOT SUITABLE FOR STATIN THERAPY

News / General News

Jun 04, 2019

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

News / General News

May 31, 2019

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA^® (gilteritinib)